Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Newsylist Editorial Desk. (2026, October 2, 2026). Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-10-02/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs

@online{newsylist_66769,
  author = {Newsylist Editorial Desk},
  title = {{Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-10-02/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs},
  note = {Tracked across 2 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s](https://www.newsylist.com/trend/2026-10-02/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs)), this event was corroborated across 2 independent sources with a live velocity of 1.